Patients presenting with chest pain and shortness of breath are time-critical emergencies that leave your lab no room for error or delay in completing cardiac diagnostic tests. Achieving the best patient outcomes requires the fastest intervention possible.
Exceptional assay performance to inform treatment decisions
Our ValuMetrix® services team has proven results: one STAT lab increased testing volume by 82.6% without adversely impacting turnaround time.
*China ValuCheck® report. Data on file.
Don't waste time waiting: with a 24-hour ready mode, Vitros® Systems are ready when you are, with no ramp-up time.
Learn how Vitros® Automation Solutions can drive faster turnaround time, improved safety and a reduction in staffing requirements.
Our assays are designed to consistently produce accurate results – the first time – so your lab can reduce errors, deliver quality results and help clinicians set the course for quality patient care.
Vitros® Troponin I ES Assay
Assay sensitivity and precision deliver reliable short-term and long-term risk information for patients with acute coronary syndrome.
Vitros Troponin I ES Assay
Performs competitively with currently available 5th-generation high-sensitivity Troponin assays
Meets American College of Cardiology/European Society Cardiology guidelines for acceptable imprecision in a high-sensitivity assay (10% coefficient of variation at the 99th percentile)
Enables accelerated rule-in/rule-out algorithms with validated clinical performance at the 99th percentile upper reference limit of normal
Helps ensure that actionable results are reported with analyzer’s automated sample indices
False positive Troponin T results have been reported in patients with kidney disease.1 Troponin I biomarker elevations are more specific for myocardial damage than Troponin T elevations.2
1. Christenson RH et al. Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study. J Appl Lab Med. 2017; March; 544-561.
2. Twerenbold R. et al., Optimal Cutoff Levels of More Sensitive Cardiac Troponin Assays for the Early Diagnosis of Myocardial Infarction in Patients With Renal Dysfunction. Circulation. 2015;131:2041-2050
Vitros® High-Sensitivity Troponin Assay*
Provides high analytical sensitivity and precision for the detection of small changes at the 99th percentile, enabling early diagnosis of acute myocardial infarction.
Vitros High-Sensitivity Troponin assay*
Features a high negative predictive value that helps reduce emergency department crowding and requires fewer tests to rule out
Meets all International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) requirements for classification as a high-sensitivity troponin assay
Shows excellent prognostic value as an aid in the assessment of cardiac-related mortality/MI and all-cause mortality over 30 days and 12 months
Is compliant for use with guidelines for management of acute coronary syndrome, including ESC, AHA and NICE
*Vitros High-Sensitivity Troponin Assay is not available in all countries. Please check with your local QuidelOrtho representative for availability.
Vitros® NT-proBNP II Assay
NT-proBNP II is more stable than BNP, an important feature when samples must be transported.1
Vitros NT-proBNP II assay:
Validated for use with ICON age-specific, cutoffs, which optimize diagnosis decisions, accounting for age and renal function with better specificity of acute dyspnea cases1-5
Long calibration interval at 70 days
Automated, on-the-fly loading of consumables and reagents with no interruptions
Intelligent sampling order to balance processing demands
Correlates well with most other NT-proBNP assays5
1. Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015-2019. doi:10.1161/CIRCULATIONAHA.110.979500
2. Masson S, Latini R, Anand IS, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: The Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006; Aug;52(8):1528-1538. doi:10.1373/clinchem.2006.069575
3. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948-954. doi:10.1016/j.amjcard.2004.12.032
4. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27(3):330-337. doi:10.1093/eurheartj/ehi631
5. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663-670. doi:10.1016/j.jchf.2014.09.001
Vitros® cardiac assay menu
Assay menu disclaimer:
This document contains information which is targeted to a wide range of audiences and could contain product details or information otherwise not valid or applicable to your country. Please remember to consult your local legal restrictions, regulations, registrations or intended uses in the country of your origin. Product availability may vary from country to country and is subject to varying regulatory requirements. New QuidelOrtho branding may not be available in all markets, subject to country specific regulatory approval. Please confirm with your local commercial team. Some assays not for use in the United States.
Related products
